$16,900,000
Committed at risk
9 mo
Longest lead
0.9 mo
Approval to launch
5 of 6
Workstreams ready
Contents
1. Everything Here Was Committed Before the Answer Was Known
Assessed 15 September 2029. The action date is 05 October 2029 and launch is 01 November 2029 — 0.9 months apart. Nothing on this page has a lead time that fits inside that gap.
| Value | |
|---|---|
| Committed before approval exists | $16,900,000 |
| Workstreams carrying pre-approval commitment | 6 |
| Longest lead time | 9 months — commercial supply build |
| Approval to launch | 0.9 months |
| Largest single exposure | $6,400,000 — commercial supply build |
Speed at launch is bought months earlier, at risk. The 01 November launch and the
$6,400,000 write-off exposure are the same decision viewed from two ends.
Commercial supply takes nine months to manufacture, release and position. Approval to launch is 0.9 months. Either the product is built before anyone knows whether it will be approved, or the launch happens nine months after approval instead of one.
Nine months of a patent that expires on a fixed date is worth far more than $6,400,000 of inventory. The exposure is real and it is the smaller of the two numbers — which is the entire calculation, and it is why every launch in this industry is built at risk.
Commercial supply takes nine months to manufacture, release and position. Approval to launch is 0.9 months. Either the product is built before anyone knows whether it will be approved, or the launch happens nine months after approval instead of one.
Nine months of a patent that expires on a fixed date is worth far more than $6,400,000 of inventory. The exposure is real and it is the smaller of the two numbers — which is the entire calculation, and it is why every launch in this industry is built at risk.
2. What Is At Risk, and What Kind of Risk It Is
| Workstream | Owner | Lead time | Committed at risk | Share | What the risk actually is |
|---|---|---|---|---|---|
| Commercial supply build | Dr. K. Oyelaran | 9 mo | $6,400,000 | 38% | ⚠ Launch quantity manufactured and released before approval. Product has a shelf life; an approval delay of more than a few months converts inventory into a write-off. |
| Field force hire and train | J. Barrington | 6 mo | $4,100,000 | 24% | Representatives hired, onboarded and trained. ⚠ Trained on the SOUGHT label, then retrained on the approved one — the second training is the unavoidable cost of the first. |
| Medical affairs field team | Dr. A. Okoye | 7 mo | $2,300,000 | 14% | Medical science liaisons deployed ahead of launch to respond to unsolicited requests. Recoverable — the capability transfers to any launch. |
| Promotional material development | J. Barrington | 4 mo | $1,800,000 | 11% | ⚠ Built against the label sought. Anything resting on a claim not granted is destroyed and rebuilt — the single most predictable write-off in a launch. |
| Patient support program | J. Barrington | 6 mo | $1,400,000 | 8% | Copay assistance infrastructure, adherence support, hub services. Vendor contracted with activation on approval. |
| Distribution network setup | G. Petrossian | 5 mo | $900,000 | 5% | Wholesaler agreements, specialty pharmacy onboarding, cold-chain qualification at depots. Largely recoverable if launch slips; contracts are dated, not consumed. |
| Total committed before approval | $16,900,000 | 100% |
Only two of the six are genuinely destroyable, and they are the two largest.
Commercial supply has a shelf life — an approval delay beyond a few months converts released inventory into a write-off, and there is no recovering it. Promotional material built on a claim that is not granted is destroyed outright.
The rest is timing risk rather than write-off risk. Distribution agreements are dated, not consumed. A trained field force and a deployed medical team are capabilities that survive a delay — they cost money to hold idle, and they do not evaporate. Distinguishing the two changes which commitments deserve a hold-point and which simply deserve a decision.
Commercial supply has a shelf life — an approval delay beyond a few months converts released inventory into a write-off, and there is no recovering it. Promotional material built on a claim that is not granted is destroyed outright.
The rest is timing risk rather than write-off risk. Distribution agreements are dated, not consumed. A trained field force and a deployed medical team are capabilities that survive a delay — they cost money to hold idle, and they do not evaporate. Distinguishing the two changes which commitments deserve a hold-point and which simply deserve a decision.
The field-force line carries a cost that looks like waste and is not. Representatives are trained on the label being sought, then retrained on the label actually granted. The second training is the unavoidable price of the first — the alternative is a sales force that cannot be deployed for six weeks after approval, in a launch window measured in weeks.
3. The Decisions, and the One That Was Reversed
| Decision | Status | Reasoning |
|---|---|---|
| Build commercial supply before approval | Committed | Not building means a launch delayed by the manufacturing lead time — roughly nine months of a patent life that expires on a fixed date. ⚠ The write-off risk is the smaller of the two numbers. |
| Train the field force on the sought label | Committed | The alternative is a field force that cannot be deployed for six weeks after approval. Retraining is cheaper than absence. |
| Build promotional material on the sought claim | ⚠ Partially reversed | ⚠⚠ Reversed in Q1 2029 once the topline made the comparative claim unlikely. Material was rebuilt against the label likely to be granted rather than the one sought — a decision that cost rework and saved more. |
| Hold pricing until the label is granted | Committed | Price cannot be set against a claim that may not exist. ⚠ It delays payer conversations into a window that was already too narrow. |
The promotional material decision was reversed in Q1 2029, and that reversal is the most
creditable thing on this page.
Material had been built against the label sought, including the comparative tolerability claim. Once the topline made that claim unlikely, the program stopped building against the sought label and rebuilt against the label likely to be granted — accepting rework it had already paid for, to avoid rework it had not yet paid for.
That is an unusual decision to take voluntarily. It admits, in a budget line, that the differentiation thesis had probably failed — months before anyone had to say so out loud. A launch plan that never revises an at-risk commitment is not being managed; it is being executed.
Material had been built against the label sought, including the comparative tolerability claim. Once the topline made that claim unlikely, the program stopped building against the sought label and rebuilt against the label likely to be granted — accepting rework it had already paid for, to avoid rework it had not yet paid for.
That is an unusual decision to take voluntarily. It admits, in a budget line, that the differentiation thesis had probably failed — months before anyone had to say so out loud. A launch plan that never revises an at-risk commitment is not being managed; it is being executed.
The pricing decision runs the other way and was correctly held. Price cannot be set against a claim that may not exist, so pricing waited for the label. The cost is that payer conversations were pushed into a window that the formulary calendar had already made too narrow — a genuine loss, accepted because the alternative was pricing against a claim and then repricing without one.
4. Readiness by Workstream
| Workstream | Position at assessment | Confidence |
|---|---|---|
| Supply and distribution | Launch quantity manufactured, released against qualified methods, positioned at wholesaler depots under validated cold chain. Twelve months of capacity reserved. | Ready |
| Field force | Hired, onboarded, trained on the sought label. Retraining on the approved label scheduled for the week following the action date. | Ready |
| Medical affairs | Field team deployed. Unsolicited-request process operating — ⚠ the only route by which off-label information may lawfully be provided, and it must be genuinely reactive. | Ready |
| Pharmacovigilance | Post-marketing safety system built and operational. ⚠ Not the IND system carried over — marketed-product reporting has different obligations and a different clock. | Ready |
| Patient support | Hub services and copay infrastructure contracted, activating on approval. | Ready |
| Payer coverage | ⚠⚠ The formulary cycle for the 2030 plan year closed before approval. Launch proceeds into exception-based access rather than formulary placement. | Not ready |
Five of six workstreams are ready, and the sixth was never capable of being ready.
Everything the program controlled is done, on time, to standard. Supply is built, the field is trained, safety is operational. The one workstream that is not ready failed on a calendar the program does not own, and its failure was visible and documented three years earlier.
This is the launch equivalent of the distinction the whole suite keeps returning to: execution and outcome are separate things. A readiness assessment that averaged these six into a single percentage would report 83% ready and communicate nothing.
Everything the program controlled is done, on time, to standard. Supply is built, the field is trained, safety is operational. The one workstream that is not ready failed on a calendar the program does not own, and its failure was visible and documented three years earlier.
This is the launch equivalent of the distinction the whole suite keeps returning to: execution and outcome are separate things. A readiness assessment that averaged these six into a single percentage would report 83% ready and communicate nothing.
5. The Limits of Being Ready
| Ready | Still cannot | Why |
|---|---|---|
| Supply in the network on day one | Make a plan cover the product | Inventory positioned at a wholesaler is available to be dispensed. It is not available to be reimbursed. |
| A trained field force | Discuss anything outside the approved label | ⚠ Promotion is bounded by the label. A representative may not raise a comparison the label does not carry, however true the underlying data. |
| Medical science liaisons in the field | Proactively fill the gap | ⚠⚠ Medical affairs may respond to unsolicited requests. It may not be used as a route to communicate what the sales force is not permitted to say — the distinction is real, it is inspected, and blurring it is a serious matter. |
| Copay assistance infrastructure | Substitute for coverage | It reduces patient out-of-pocket on a non-preferred tier at the manufacturer's expense. It buys persistence, not access, and it makes each unit less profitable. |
Launch pressure produces a serious compliance failure at exactly one of those points.
A commercial organization holding a claim it believes is true, a sales force forbidden to make it, and a medical team permitted to discuss it only when asked, is a structure under obvious strain. The strain is intentional — it is what separates scientific exchange from promotion.
The control is that medical affairs reports outside the commercial line, which is the same independence pattern as the quality function and the data monitoring committee. The organization is designed so that the people who most want a boundary moved are not the people who could move it.
A commercial organization holding a claim it believes is true, a sales force forbidden to make it, and a medical team permitted to discuss it only when asked, is a structure under obvious strain. The strain is intentional — it is what separates scientific exchange from promotion.
The control is that medical affairs reports outside the commercial line, which is the same independence pattern as the quality function and the data monitoring committee. The organization is designed so that the people who most want a boundary moved are not the people who could move it.
6. What This Assessment Would Have Said Two Years Earlier
Recorded because the useful version of a readiness assessment is the one written while something can still be done.
| At Gate 5, Sep 2028 | Actionable then? |
|---|---|
| Payer coverage will not be ready, because the 2030 formulary cycle closes before approval | ⚠ No. The dates were fixed. Knowable, not changeable. |
| Promotional material built on the comparative claim is likely to be written off | Yes — and it was acted on, in Q1 2029, once the topline was available. |
| Supply must be built nine months before an approval nobody can guarantee | Yes, and the decision to accept the exposure should be minuted rather than absorbed into a launch budget. |
| Pricing cannot be set until the label is granted, compressing payer engagement | ⚠ Partially. Engagement on everything except price could have started earlier, and the advisory board program was already behind. |
Three of the four were knowable at Gate 5 and two were actionable. Only one was acted on.
That is not incompetence — it is what happens when a launch team forms late and inherits commitments made by a program that was, correctly, focused on generating evidence. The launch organization did not exist in a form capable of asking these questions until well after the answers had stopped mattering.
The transferable version: a launch readiness assessment run twelve months before launch is a status report. Run at Gate 5, it is a decision document — and the difference is entirely whether anybody can still change anything.
That is not incompetence — it is what happens when a launch team forms late and inherits commitments made by a program that was, correctly, focused on generating evidence. The launch organization did not exist in a form capable of asking these questions until well after the answers had stopped mattering.
The transferable version: a launch readiness assessment run twelve months before launch is a status report. Run at Gate 5, it is a decision document — and the difference is entirely whether anybody can still change anything.